What was studied?
The trial randomized 579 adults who had already lost at least 5% of body weight during a 12-week intensive lifestyle program. It compared tirzepatide with placebo for another 72 weeks.
What did the researchers report?
Participants assigned tirzepatide had additional average weight reduction, while the placebo group gained some weight from randomization. Gastrointestinal events were the most common adverse effects.
What are the limits?
The participants were selected for an initial response to lifestyle intervention. Their results do not represent every person beginning weight management, and the study does not validate unsupervised use of a research material.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.